Global Erectile Dysfunction Market 2016-2020

This market research study analyzes the key players in the global erectile dysfunction market such as Bayer, Boston Scientific, Coloplast, Eli Lilly, and Pfizer. A comprehensive analysis of this market is also presented by product (drugs and devices), by type of drugs (Cialis, Viagra, and Levitra), by device (inflatable penile implant and semi-rigid rod implant), and by geography (Americas, APAC, and EMEA).

Overview of the erectile dysfunction market

According to the erectile dysfunction market analysis, the global erectile dysfunction market is anticipated to witness slow growth and will reach close to USD 4 billion by the end of 2020. Globally, there has been an increase in the number of people with prostate cancer, which is one of the most common types of cancers among men. The treatment involves the removal of the prostate gland, which can result in impaired sexual function in at least half of the men who undergo this treatment. Prostate cancer does not directly cause erectile dysfunction (ED). However, the treatment methods, such as surgery with radical prostatectomy, hormone therapy or radiation therapy can cause ED among men.

One of the emerging trends propelling this market’s growth prospects is the augmented demand for penile implants. In many countries, the demand for penile implants is increasing as a result of the growing number of ED cases. This has led many pharmaceutical firms to invest in the R&D of new technologies to develop new products and upgrade their existing offerings. Furthermore, many countries in APAC such as China and Japan have a large older adult population. Penile implants were first introduced in China in 2002 but witnessed limited adoption due to its high cost and poor acceptance. However, by reviving the global economy and an increase in disposable income, the market for penile implants is likely to show a gradual growth during the forecast period and will increase the erectile dysfunction market size.

Competitive landscape and key vendors

The global erectile dysfunction market is oligopolistic in nature and is dominated by a few large companies around the world including Eli Lilly, Pfizer, Boston Scientific, Coloplast, Bayer, and Apricus Biosciences. Presently, the market has a broad range of solutions to treat ED, including ED drugs, ED devices or implants, intraurethral injections, and vacuum erection devices. The demand for ED solutions will be high in APAC countries such as China, South Korea, and Japan, which have a growing older adult population. Furthermore, the market is likely to witness many patent expirations and players competing on various factors, such as price, availability, brand, and variety.

Key vendors in this market are 

• Bayer
• Boston Scientific
• Coloplast
• Eli Lilly
• Pfizer

Other prominent vendors in the market are Apricus Biosciences, Cristalia Produtos Quimicos Farmaceuticos, Dong-A Socio, Endo Pharmaceuticals, Futura Medical, Meda Pharmaceuticals, Promedon, SK Chemical, Teva Pharmaceuticals, Vivus, and Zephyr Surgical Implants (ZSI).

Product segmentation and analysis of the erectile dysfunction market

• ED drugs
• ED devices

During 2015, the ED drugs segment led the erectile dysfunction drugs market and accounted for almost 80% of the market share in terms of revenue. This segment is mainly dominated by three drugs, namely, Viagra by Pfizer, Cialis by Eli Lily, and Levitra by Bayer owing to factors such as ease of use and availability. Also, the introduction of new drugs such as Zydena, Stendra/Spedra, and Vitaros in the coming years is likely to have a positive impact on the market. Moreover, many generic drugs with a chemical composition similar to existing branded ED drugs like Viagra and Cialis are expected to be launched during the forecast period. For instance, Teva Pharmaceuticals will launch its generic version of Viagra in the US in December 2017, which will break the market monopoly of the original Viagra by Pfizer in the US.

Geographical segmentation and analysis of the erectile dysfunction market

• Americas
• APAC
• EMEA

In terms of geography, the Americas dominated the global erectile dysfunction market and is expected to hold close to 50% of the market share by 2020. The growth of this market in the Americas is attributed to the presence of pioneer ED drugs and penile implants companies such as Pfizer, Boston Scientific, and Coloplast in the region. Although the ED market is declining in the Americas, extended patent rights for Viagra till 2020 is likely to maintain a steady demand for the drug during the forecast period. Furthermore, several pipeline drugs such as Vitaros and Uprima are in different stages of development, which will fuel a huge demand for the market during the forecast period.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global erectile dysfunction market?
• What are the key market trends impacting the growth of the global erectile dysfunction market?
• What are the challenges to market growth?
• Who are the key vendors in the global erectile dysfunction market?
• What are the market opportunities and threats faced by the vendors in the global erectile dysfunction market?
• What are the trending factors influencing the market shares of the Americas, APAC, and EMEA?
• What are the key outcomes of the five forces analysis of the global erectile dysfunction market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Penile Implants Market 2016-2020
• Sexual Wellness Market in the US 2016-2020
• Global Wellness Tourism Market 2016-2020